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              Quercetin is a flavonoid found in commonly consumed fruits and vegetables that has 
exhibited powerful antioxidant and anti-inflammatory properties in rodents and in vitro. In 
humans, the effect of quercetin on exercise induced oxidative stress and inflammation is still 
equivocal and need to be further investigated. A powerful antioxidant such as quercetin may 
inhibit the high levels of oxidative stress and inflammation associated with the high volume and 
intensity of exercise training seen with endurance-trained individuals. 
 
PURPOSE: To determine the effect of 28 days of daily quercetin supplementation on intensive 




METHODS: Thirteen trained cyclists (VO2peak 58.8 ± 3.9 ml/kg/min) were recruited for this 
study from the University of Texas at Austin and the local Austin, Texas community and 
participated in this placebo controlled, randomized, crossover designed study. After initial 
assessment of baseline data (VO2peak, lactate threshold, and two familiarization time trials), 
participants began daily supplementation with either an antioxidant supplement containing 
vitamins and quercetin (Q-VIT: 1000mg quercetin, 820mg Vitamin C, 40mg Vitamin B3) or the 
same vitamin supplement without quercetin (VIT: 820mg Vitamin C, 40mg Vitamin B3). A 
simulated time trial using an electromagnetically braked cycle ergometer in which subjects had 
to complete a set amount of work (kJ) as fast as possible was performed on the last day of 
supplementation.  
Blood collection was performed at three time points of the time trial days: before exercise (PRE), 
after warm up (MIN 20), and immediately after time trial exercise (POST). Measured plasma 
markers were Interleukin-6 (IL-6), C-Reactive Protein (CRP), and Interleukin-10 (IL-10). 
 
RESULTS:  Q-VIT compared to VIT had no effect on pre, min 20 and post exercise plasma IL-
6, CRP, and IL-10 ( P= 0.7, 0.08, and 0.32 respectively). However there was a trend that Q-VIT 
lowered plasma CRP compare to VIT ( P = 0.08). 
 
CONCLUSION: Chronic supplementation for 28 days with a quercetin based antioxidant 
supplement did not affect plasma cytokine before during or after exercise. The results of the 
current study suggest that chronic supplementation with quercetin does not influence plasma 
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             Regular physical activity is well known to reduce the incidence of or attenuate the 
detrimental effects of various disease states.  However, exercise, particularly intense exercise can 
lead to increased inflammation [1] and oxidative stress [2] following acute bouts of exercise. 
Antioxidant supplementation has the potential to attenuate exercise-induced oxidative stress and 
inflammation [3]. Specifically, there has been a large interest in quercetin, a common flavonoid 
found in grapes, apples, cherries, onions, citrus fruits, broccoli, and tea [4]. Epidemiologic data 
indicate reduced rates of cardiovascular disease [5]and various types of cancer [6-8] in groups 
self-selecting diets high in quercetin. The flavonoid quercetin has been associated with numerous 
potential health benefits in rodents and in vitro including anti-viral [9], hepatoprotective, 
antifibrogenic [10], antiatherogenic [11], anti-inflammatory [12], and potent antioxidant 
capabilities [13]. Several recent quercetin based supplementation studies in human athletes have 
focused on potential influences as a countermeasure to post-exercise inflammation and oxidative 
stress, however, the results remain equivocal [14-20]. There are several potential reasons for 
inconsistent results including the training states of subjects, supplementation durations, the 
timing of last supplement intake, and the types of exercise and exercise protocol. 
           Due to the mixed results of the previous studies, the goal of this study is to clarify the 
effect of chronic quercetin supplementation on exercise induced cytokine response in trained 
cyclists. We hypothesize that the powerful antioxidant properties of quercetin will reduce plasma 
cytokine and/or attenuate exercise induced cytokine response in trained cyclists after daily 





REVIEW OF LITEERATURE 
             The following literature review will discuss the flavonoid quercetin and its associated 
properties in cell culture, animal, and human experimental trials. Specifically, the review will 
focus on the antioxidant and anti-inflammatory property of quercetin and its potential role in 
attenuate exercise induced oxidative stress and inflammation. Studies that have evaluated the 
effect of quercetin based supplements on exercise induced cytokine response and inflammation 
will be analyzed. 
Quercetin 
              Flavonoids occur naturally in fruits, vegetables and beverages such as tea and wine. 
Quercetin is the major flavonoid which belongs to the class called flavonols. Quercetin is found 
in many common foods including apples, tea, onions, nuts, berries, cauliflower, cabbage and 
many other foods. Quercetin has been shown to be an excellent in vitro antioxidant. Within the 
flavonoid family, quercetin is the most potent scavenger of reactive oxygen species (ROS) [21, 
22], and reactive nitrogen species (RNS) [23, 24]and these antioxidative capacities of quercetin 
are attributed to the presence of two antioxidant pharmacophores within the molecule that have 
the optimal configuration for free radical scavenging, i.e. the catechol group in the B ring and the 
OH group at position 3 of the AC ring [25]. Moreover, quercetin is suggested to substantially 
empower the endogenous antioxidant shield due to its contribution to the total plasma 
antioxidant capacity which is 6.24 times higher than the reference antioxidant trolox, whereas for 
example the contribution of both vitamin C and uric acid virtually equals that of trolox [26].  
Quercetin is also known to possess strong anti-inflammatory capacities [27, 28]. Several in vitro 
studies using different cellines have shown that the flavonoid is capable of inhibiting 
lipopolysaccharide (LPS) induced cytokine production. For instance, quercetin inhibits LPS 
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induced tumor necrosis factor – alpha (TNFα) production in macrophages [29] and LPS-induced 
interleukin-8 (IL-8) production in lung cells [30]  Moreover, in glial cells it was even shown that 
quercetin can inhibit LPS-induced mRNA levels of two cytokines, i.e. TNFα and interleukin-1 
alpha (IL-1α) [31]. A possible explanation for these anti-inflammatory effects of quercetin may 
be found in the interplay between oxidative stress and inflammation. ROS are not only involved 
in the occurrence of oxidative stress, but also in the promotion of inflammatory processes via 
activation of transcription factors such as nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) and activator protein (AP)-1 which induce the production of cytokines like 
interleukin-6 (IL-6) [12, 32]. Consequently, scavenging ROS would not only prevent the 
occurrence of oxidative stress but also help mitigate inflammation. Indeed, it has already been 
shown that quercetin can inhibit the production as well as the gene expression of TNFα via 
modulation of NF-κB in human peripheral blood mononuclear cells [33]. A possible mechanism 
behind this modulation was reported to be the inhibition of the degradation of the inhibitory part 
(IκBα) of this transcription factor [34]. Therefore, quercetin can potentially attenuate cytokines 
production by directly neutralizing ROS and/or inhibiting the activity of redox-sensitive signal 
transduction pathways. 
 
Bioavailability of Quercetin 
             Because the beneficial effects of quercetin are largely dependent on its bioavailability 
after oral administration, the absorption, distribution, metabolism, and excretion of quercetin 
have been studied extensively in both laboratory animals and humans. Although initial reports 
indicated that bioavailability of quercetin was limited, recent evidence suggests otherwise [35]. 
Large scale epidemiological studies support the availability of quercetin in human plasma and 
serum when volunteers were supplemented with doses ranging from 50-1000mg/day.  Quercetin 
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serum and plasma levels rose in a direct dose dependent manner [36, 37].  However, the levels of 
quercetin within the plasma varied greatly among the population with no relationship to 
demographic or lifestyle factors [37].  Jin et al. [37] reported that the net increase in blood was 
332 and 516 micrograms/L, respectively, for the 500 and 1,000 mg/d dose after twelve weeks of 
quercetin supplementation. Data from their study also showed that the dose response increase in 
plasma quercetin was achieved within the first month and maintained for the rest of the study, 
which supports the rationale that choosing 28 days as supplementation duration in our study. 
Literature indicates that isoquercetin (glycosylated quercetin) is more completely absorbed than 
is quercetin in aglycone form, and that the simultaneous ingestion of quercetin with vitamin C, 
folate, and additional flavonoids improves bioavailability of quercetin [38-40]. A possible 
explanation for this increased absorption, resulting in a higher plasma peak concentration and an 
increased bio-availability, is the facilitation of glycoside absorption by either deglycosylation [41, 
42] or carrier-mediated transport [43, 44]. For example, the glucose molecule in isoquercetin 
may favor the use of the sodium-dependent glucose transport pathway of the intestinal brush 
border membrane, improving absorption rates when compared with the pure aglycone form of 
quercetin [45]. Two or more flavonoids ingest together may also increase bioavailability and 
decrease elimination via competitive inhibition of glucuronide and sulfate conjugation in both 
the intestine and the liver and via inhibition of efflux transporters [40]. It has been shown that the 
half live of the quercetin metabolites are rather high, i.e. 11 to 28 h. This indicates that, upon 
repeated quercetin supplementation, they could attain a considerable plasma level [39, 46]. 
Furthermore, Davis et al. [35] reported that quercetin can be detected in plasma within 15-30 min 
after ingestion of a 250 or 500 mg quercetin chew preparation, reaching a peak concentration at 
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approximately 120-180 min. This supports the rationale that subjects ingested quercetin 
supplement two hours before starting of exercise in our study. 
 
Exercise and Oxidative Stress and Inflammation 
            In response to endurance exercise, oxygen (O2) consumption increases 10- to 20-fold 
systemically and as much as 100- to 200-fold at the level of the skeletal muscle, resulting in 
substantially increased mitochondrial electron flux. ROS ‘‘leaking’’ from the mitochondria 
during exercise are considered a main source of oxidative stress [47]. Other potential sources of 
ROS during exercise include enhanced purine oxidation, damage to iron-containing proteins, 
disruption of Ca2+ homeostasis [48], and Nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase [49]. These exercise-induced ROS are also thought to modulate acute-phase 
inflammatory responses [50]. Exercise-induced tissue damage and/or increased reactive oxygen 
species (ROS) production stimulate cytokine production, upregulating the inflammatory cascade 
[50-52]. Initially, pro-inflammatory cytokines, TNFα and IL-1α are produced, stimulating IL-6 
production [51]. IL-6, the primary mediator of the acute-phase reaction, stimulates production of 
acute-phase proteins, including C-reactive protein (CRP), and restricts the extent of the 
inflammatory response by enhancing production of anti-inflammatory cytokines such as 
interleukin-10 (IL-10) [52, 53]. Neutrophils, monocytes, and lymphocytes recruited to the site of 
inflammation also produce ROS and proteolytic enzymes to clear and repair damaged tissue [50, 
51, 53].  
           However, post exercise cytokine response may be independent of oxidative stress and 
muscle damage induced by exercise. In recently years, it became clear that contracting human 
skeletal muscle releases significant amounts of interleukin (IL)-6 into the circulation during 
prolonged single-limb exercise [54]. This increase is followed by the appearance of IL-1 receptor 
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antagonist (IL-1ra) and the anti-inflammatory cytokine IL-10. Of note, the cytokine response to 
exercise and sepsis differs with regard to TNFα. Thus, the cytokine response to exercise is not 
preceded by an increase in plasma TNFα. It appears that, unlike IL-6 signaling in macrophages, 
which seems to be dependent upon the activation of the NF-κB signaling pathway, intramuscular 
IL-6 expression is regulated by a network of signaling cascades that among other pathways are 
likely to involve crosstalk between the Ca2+/nuclear factor of activated T-cells (NFAT) and 
glycogen/p38 mitogen-activated protein kinase (MAPK) pathways. Thus, when IL-6 is produced 
by macrophages, it leads to an inflammatory response, whereas muscle cells produce and release 
IL-6 without activating classical pro-inflammatory pathways[55]. 
 
Quercetin and Exercise Induced Inflammation 
 
 
Chronic Supplementation  
             The strong anti-inflammatory capacities of quercetin in vitro have led several human 
studies to investigate the influence of quercetin supplementation on cytokines response to 
exercise. A study [14]used 40 trained male cyclists in a double-blind, randomized, cross 
sectional, placebo controlled investigation.  Subjects ingested quercetin ( pure quercetin 1,000 
mg/day mixed in orange Tang powder with powdered food coloring) or placebe for three weeks 
before and during a 3-day period in which subjects cycled for 3 h/day at 57% maximal work rate 
to test the influence of quercetin on exercise-induced changes in plasma cytokines and muscle 
and leukocyte mRNA. Quercetin supplementation significantly increased plasma quercetin levels, 
however, quercetin only diminished postexercise expression of leukocyte IL-8 and IL-10 mRNA, 
and exhibited no influence on postexercise increases in plasma cytokines and any of  muscle 
measure, including NF-KB content, cytokine mRNA, or COX-2 mRNA expression. In the same 
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study, McAnulty et al. [15] also showed that quercetin did not affect oxidative stress, and plasma 
antioxidant capacity. 
             Another three weeks quercetin supplementation was done by Neiman et al. [16]. This 
study was a double-blind, cross sectional, placebo controlled study with ultramarathon runners at 
the 160-km Western States Endurance Run (WSER). Sixty-three runners ingested 1,000 mg/day 
quercetin or placebo each day for three weeks and just prior to WSER, but did not ingest 
additional supplements until after post-race blood samples were acquired (an average of 27 h 
later). Plasma quercetin levels dropped to very low levels in the quercetin group and were not 
much different from the placebo group post-race. There were no significant groups differences in 
proinflammatory and anti-inflammatory plasma cytokines, cortisol, serum CRP, and creatine 
kinase (CK) even through there were significant prerace to postrace increases in there measures.  
            Abbey al el. [19] performed a crossover, randomized, double-blind, placebo controlled 
study with fifteen recreationally activity young adult men to test the influence of one week 
quercetin supplementation on repeated-sprint performance, xanthine oxidase (XO) and 
inflammation. The supplementation was a 6% carbohydrate commercial drink for placebo, or 
that drink with 500 mg of quercetin-3-glucoside for quercetin group, consumed twice a day. 
Quercetin did not improve repeated-sprint performance nor attenuate XO activity and IL-6 
response after sprint exercise. 
Mixed with other flavonoids 
              There is increasing support for coingestion of quercetin with other flavonoids and food 
components to improve and extend quercetin’s bioavailability and bioactive effects. Nieman et al. 
[17] employed the same exercise protocol as previously described to investigate quercetin’s 
influence on exercise induced acute inflammatory response and markers of mitochondrial 
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biogenesis. Thirty-nine trained cyclists supplemented for 2 weeks on placebo, quercetin, or 
quercetin with epigallocatechin 3-gallate (EGCG). Subjects ingested four soft chews per day, 
each quercetin chew contained with 250 mg of quercetin, 250 mg of vitamin C, 10 mg of 
niacinamide, and 200 mg of folic acid. These nutrients were included in the quercetin group to 
facilitate quercetin absorption in the small intestine. Each Q–EGCG chew contained all 
Quercetin group ingredients with 30 mg of EGCG from green tea extract, 100 mg of isoquercetin, 
and 100 mg of N3-polyunsaturated fatty acids (N3- PUFA) (55 mg of eicosapentaenoic acid 
(EPA) and 45 mg docosahexaenoic acid (DHA)) from fish oil. These food components were 
included to improve quercetin bioavailability and extend its bioactive effects. No markers of 
mitochondrial biogenesis were elevated, however, there were significantly lower levels of CRP, 
IL-6, and IL-10 after exercise in the quercetin with EGCG group immediately following exercise.  
             A more recent study performed by McAnulty et al. [18] mixed quercetin with other 
compounds. This study examined the effects of 1,000 mg quercetin + 1,000 mg vitamin C (QC); 
1,000 mg quercetin, 1,000 mg vitamin C, 400 mg isoquercetin, 30 mg epigallocatechin gallate, 
and 400 mg n-3 fatty acids (QFO); or placebo (P), taken each day for 2 week before and during 3 
d of cycling at 57% Wmax for 3 hr on plasma oxidative stress (F2-isoprostanes) and antioxidant 
capacity. QC and QFC effectively reduced postexercise increase in F2-isoprostanes with no 
changes of antioxidant capacity between groups. This result indicated that the effect of QC and 
QFC on F2-isoprostanes independent to changes in plasma antioxidant capacity.   
              The acute effect of quercetin base supplementation has also been done. Konrad et al. [56] 
examined the anti-inflammatory and immune-modulating influence of a single dose of a 
quercetin-base supplement consumed by endurance athletes 15 minutes before a 2-hour run at 
70-75% VO2max. In contrast to the two weeks study with similar supplementation [17], a 
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mixture of 1000mg quercetin, 120mg EGCG, and other vitamins provided no benefit to the post-



























         Endurance-trained male (n = 11) and female (n = 2) cyclists (age 30.1 ± 7.1 y, body mass 
67.8 ± 10.81 kg, height 173.41 ± 9.15 cm, VO2max 58.83 ± 3.93 ml/kg/min) (Table 1) were 
recruited for this study from the University of Texas at Austin and local Austin, Texas 
community. A trained cyclist was defined as an individual that regularly competes in cycling 
racing and competitions and had a minimum VO2max of 53 ml/kg/min for men and 45 
ml/kg/min for women on the cycle ergometer. Subjects had to be training a minimum of 7 hours 
per week on the bike and between 18 and 40 years old. During the entire duration of the study, 
the subjects were required to maintain their current volume and intensity of cycling training. Any 
potential participants that were planning on tapering or vastly increasing volume or intensity of 
training during the 12 weeks following the screening appointment were not included in the study. 
Subjects completed a questionnaire prior to participation to assure they met the inclusion criteria, 
which included the following: must be healthy, non-smoking, and have no history of chronic 
disease. Consumption of anti-inflammatory (Advil, Motrin, etc.) or anti-oxidant supplements 
(supplemental vitamins/minerals, etc.) could not be consumed during the entire testing period. 
Subjects must have no history of hypertension, history of or current antihypertensive drugs use, 
or use of lipid-lowering, or anti-inflammatory steroid medication; no active weight loss > 5 kg in 
the prior 3 months, and no history of kidney dysfunction. Subjects must not use antidepressant 
drugs such as Selective Serotonin Reuptake Inhibitors (SSRI) during the testing period. The 
study was conducted under a protocol approved by the University of Texas at Austin Institutional 




          This study was a double blind, randomized, placebo controlled, crossover experiment. 
There were two testing periods lasting 28 days each with a 1 week washout between them. 
Preliminary testing for determination of each subject’s maximal oxygen consumption (VO2max ) 
and lactate threshold (LT) along with two familiarization time trials (FAM1, FAM2) were 
performed in a 2 week period prior to the start of the testing period. During each testing period, 
the subject would be randomly assigned to ingestion of a daily quercetin based vitamin 
supplement (Q-VIT) or a vitamin supplement without quercetin (VIT). On the last day of each 
testing period (Day 28) the subject returned to the lab to perform a simulated time trial on a cycle 
ergometer. Combined with the preliminary testing, there were a total of six visits to the Human 
Performance Laboratory for each subject. The preliminary phase of testing consisted of the first 
four visits: VO2max testing, LT testing, FAM1, and FAM2. The testing period consisted of two 
visits to the lab in which the subjects would perform the simulated time trial on Day 28 of 
supplementation (TT1 and TT2). Blood draws were collected before exercise(PRE), after warm 
up(MIN 20), and after time trial (POST) in each the time trials for analyzing plasma 
concentrations of interleukin-6, C-reactive protein (CRP), and interluukin-10.  
 
Activity and Diet Control  
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            Subjects were asked to refrain from any major changes in exercise training for the 
duration of the study. Subjects recorded daily training during the first supplementation periods 
that had to be closely matched during the second treatment period. All subjects were required to 
refrain from exercise the day before their time trial.  
             Diet was recorded during the three days leading up to the time trial during the first 
treatment period. This diet had to be replicated three days prior to the time trial during the second 
treatment period. A minimum of 2 hours was required between the time trial and the subject’s 
last meal. 
Supplementation  
              Subjects supplemented twice daily with a chewable flavored tablets. Two tablets were 
ingested in the morning and two were ingested in the evening with 12 hours part. The Q-VIT 
tablets each contained 250 mg quercetin, 205 mg Vitmain C, and 10 mg Vitamin B3 for a total of 
1000 mg/day quercetin, 820 mg/day Vitamin C, and 40 mg/day Vitamin B3. The placebo chews 
(VIT) contained identical vitamin ingredients minus the quercetin. The placebo chews had a 
similar external appearance and flavor. On the final day of supplementation, subjects were 
instructed to ingest all four of the daily chews two hours before the time trial. 
Exercise Trial  
Upon arrival to the laboratory, subjects were seated and rested for five minutes before initiation 
of any measures or activity. Before and after a 20 minute warmup ride on the cycle ergometer at 
70% VO2max, subjects were seated and blood was drawn via venipuncture of an antecubital 
vein. After the second blood draw, the subjects began the exercise time trial on the cycle 
ergometer. The goal of the time trial was to complete a set amount of work as quickly as possible. 
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The required Kilojoules that the participant needs to complete during the time trial was 
calculated from the equation below: 
• Ttworkrate = watts = Joules/sec  
• Joules/sec X 2400sec = Joules  
• Joules/1000 = Time Trial kJ (TT kJ) 
The first 20 minutes of the time trial were set at a fixed workrate equal to the aforementioned 
Ttwokrate. Computer software (Lode Ergometer Manager V 9.1, Lode; Gronigen, Netherlands) 
was used to program the cycle ergometer to have a fixed power (fixed power mode) independent 
of cadence during the first 20minutes. After the first 20 minutes, the cycle ergometer would 
change to a cadence dependent mode (linear mode). In this mode, the subjects could increase or 
decrease power output (watts) by increasing or decreasing cadence from a previously established 
preferred cadence or by requesting the investigators to raise the Ttworkrate. Workrate was raised 
or lowered in pre-determined increments equal to 5% of their Ttworkrate. The subjects were told 
when they had completed 60, 70, 80, 90, and 95 percent of the work they must complete and the 
approximate time left until completion at their current power output. Subjects were verbally 
encouraged at these intervals to complete the time trial as fast as possible. Time to completion 
was recorded as the total time to complete TT kJ. The subject would immediately move off of 
the cycle ergometer to a seated position for the final blood draw. Aside from the pacing 
information, the subjects were blinded from all performance information until participation in the 





Blood was drawn via venipuncture from an antecubital vein before exercise (PRE), after the 
warm up (MIN 20), and after completion of the time trial (POST) for both VIT and Q –VIT 
treatments. All blood samples collected were immediately transferred to K2 EDTA collection 
tubes (BD Vacutainer, Franklin Lakes, NJ), centrifuged at 2,000 g for 15 minutes at 4°C, and 
plasma was aliquoted and then stored in at -80°C until later analysis. All samples for each 
subject were performed in duplicate and within the same plate to decrease interkit assay 
variability. Enzyme-linked immunosorbent assays (ELISA) were used, in accordance with the 
manufacturer protocol, to measure total plasma concentrations of interleukin-6 (IL-6 high 
sensitivity), C-reactive protein (CRP), and interluukin-10 (IL-10 high sensitivity) (R&D Systems, 
Inc., Minneapolis, MN). 
Interleukin-6 
Interluekin-6 was measured in duplicate using the enzyme-linked immunosorbent method. 
Samples of plasma were pipetted into antibody, specific to IL-6, pre-coated wells and any IL-6 
present was bound by the immobilized antibody. After washing away any unbound substances, 
an enzyme-linked antibody specific for IL-6 was added to the wells. Following a wash to remove 
any unbound antibody-enzyme reagent, a substrate solution was added to the wells. After an 
incubation period, an amplifier solution was added to the wells and color developed in 
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proportion to the amount of IL-6 bound in the initial step. The color development was stopped 
and intensity of the color was measured using a spectrophotometer plate reader at 490nm and 
650nm. Subtracted reading at 650nm from the reading at 490nm. This subtraction was to correct 
for optical imperfections in the plate. The minimum detectable concentration was 0.039 pg/mL. 
The intra-assay coefficient of variation was 4.0%. 
C-reactive protein 
C-reactive protein was measured in duplicate using the enzyme-linked immunosorbent method. 
Samples of plasma were pipetted into antibody, specific to CRP, pre-coated wells and any CRP 
present was bound by the immobilized antibody. After washing away any unbound substances, 
an enzyme-linked antibody specific for CRP was added to the wells. Following a wash to remove 
any unbound antibody-enzyme reagent, a substrate solution was added to the wells and color 
developed in proportion to the amount of IL-6 bound in the initial step. The color development 
was stopped and intensity of the color was measured using a spectrophotometer plate reader at 
450nm and 540nm. Subtracted reading at 650nm from the reading at 450nm. This subtraction 
was to correct for optical imperfections in the plate. The minimum detectable concentration was 
0.010 ng/mL. The intra-assay coefficient of variation was 4.6%. 
Interluukin-10 
Interluekin-10 was measured in duplicate using the enzyme-linked immunosorbent method. 
Samples of plasma were pipetted into antibody, specific to IL-10, pre-coated wells and any IL-10 
present was bound by the immobilized antibody. After washing away any unbound substances, 
an enzyme-linked antibody specific for IL-10 was added to the wells. Following a wash to 
remove any unbound antibody-enzyme reagent, a substrate solution was added to the wells. After 
an incubation period, an amplifier solution was added to the wells and color developed in 
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proportion to the amount of IL-10 bound in the initial step. The color development was stopped 
and intensity of the color was measured using a spectrophotometer plate reader at 490nm and 
690nm. Subtracted reading at 690nm from the reading at 490nm. This subtraction was to correct 
for optical imperfections in the plate. The minimum detectable concentration was 0.09 pg/mL. 
The intra-assay coefficient of variation was 6.7%. 
 
Statistical Analysis 
              Plasma IL-6, CRP and IL-10 were analyzed with a two-way repeated measures ANOVA 
to analyze interaction of treatment and time. The criterion for significance was set at p< 0.05. All 
statistics were calculated with IBM SPSS Statistics software, version 19. Results are reported as 











Blood was collected before exercise (PRE), after the warm up (MIN 20), and after completion of 
the time trial (POST). The concentration of plasma interleukin-6 was expressed as picograms per 
milliliter (pg/mL). In VIT treatment, the plasma IL-6 for PRE, MIN 20, and POST were 3.59 ± 
0.34 pg/ml, 4.63 ± 0.37 pg/ml, and 26.52 ± 1.54 pg/ml, respectively. Plasma IL-6 was 
significantly higher at (POST) compared to both MIN 20 (p < 0.01) and PRE (p < 0.01).  Plasma 
IL-6 in treatment VIT was also significantly higher at MIN 20 compared to PRE (p < 0.01). In Q 
– VIT treatment, the plasma IL-6 for PRE, MIN 20, and POST were 3.922±0.415 pg/ml, 4.67 ± 
0.56 pg/ml, and 24.96 ±1.98 pg/ml, respectively. Plasma IL-6 was significantly higher at POST 
compared to both MIN 20 (p < 0.01), and PRE (p< 0.01).  Plasma IL-6 in treatment Q – VITwas 
also significantly higher at MIN20 compared to PRE (p < 0.01). There was no significant 
difference between treatment VIT and Q – VIT. (p= 0.70). 
C-Reactive Protein 
The concentration of plasma C-Reactive Protein was expressed as in nanograms per milliliter 
(ng/mL). In VIT treatment, the plasma CRP for PRE, MIN 20, and POST were 11.64 ± 2.72 
ng/ml, 12.59 ± 2.47 ng/ml, and 12.94 ± 2.86 ng/ml, respectively. In Q – VIT treatment, the 
plasma CRP for the same data points were 8.36 ± 2.75 ng/ml, 8.84 ± 3.08 ng/ml, and 8.84 ± 3.41 
ng/ml, respectively. There was an overall time effect of exercise on plasma CRP concentration (p 
< 0.01).  Plasma CRP concentration was significantly higher at MIN 20 compared to PRE (p < 
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0.01). There was no significant difference between treatments VIT and Q – VIT, although there 
was a trend that VIT was higher than Q – VIT (p = 0.08). 
Interleukin-10 
The concentration of plasma interleukin-10 was expressed as picograms per milliliter (pg/mL).In 
VIT treatment, the plasma IL-10 for PRE, MIN 20, and POST were 0.38 ± 0.11 pg/ml, 0.36 ± 
0.09 pg/ml, and 0.59 ± 0.10 pg/ml, respectively. Plasma IL-10 was significantly higher at POST 
compared to MIN 20 (p = 0.03). In Q – VIT treatment, the plasma IL-10 for the same data points 
were 0.273±0.036pg/ml, 0.266±0.027pg/ml, and 0.52 ± 0.12 pg/ml, respectively. Plasma IL-10 
was significantly higher at POST compared to MIN 20 (p = 0.046). There was no significan 
difference between treatment VIT and Q – VIT (p = 0.32). 
Plasma Quercetin  
 
 
Supplementation with Q-VIT was successful in significantly raising plasma quercetin 
concentration when compared to the VIT treatment. Q-VIT quercetin plasma concentration was 











Table 1 – Characteristic of research participates  






30.1 ± 7.1 
Height (cm) 
 
173.4 ± 9.1 
Weight (kg) 
 
67.8 ± 10.8 
BMI 
 




58.83 ± 3.93 
VO2max (l/min)   3.98 ± 0.62 
 
Table 1: Characteristics of research participates. Presented as MEAN ± SEM. (n=11) 




















Figure 1: Plasma Interleukin-6 concentration reported in picograms per milliliter (pg/mL). 
Treatments were a vitamin supplement (VIT) and a vitamin supplement with quercetin (Q-VIT). 
Presented as MEAN ± SEM. (n=11). * VIT and Q - VIT were significantly greater than PRE (p 
< 0.01). # VIT and Q - VIT was significantly greater than minute 20 (p < 0.01). There were no 







































 Figure 2: Plasma C-Reactive Protein concentration reported in nanograms per milliliter (ng/mL).  
Treatments were a vitamin supplement (VIT) and a vitamin supplement with quercetin (Q-VIT). 
Data presented as MEAN ± SEM. (n=11) Overall time (p < 0.01). * MIN 20 was significantly 


















































Figure 3: Plasma Interleukin-10 concentration reported in picograms per milliliter (pg/mL). 
Treatments were a vitamin supplement (VIT) and a vitamin supplement with quercetin (Q-VIT).  
Data presented as MEAN ± SEM. (n=11). * VIT and Q - VIT significantly greater than MIN 20 

































            The primary finding of this study was that there was a time effect of exercise on plasma 
Interleukin-6 (IL-6), C-reactive protein (CRP), and Interleukin-10 (IL-10) concentrations for 
both VIT and Q - VIT treatments. Our results show that intense endurance cycling exercise 
significantly increased both pro-inflammatory (IL-6) and anti-inflammatory cytokines (IL-10) 
after daily supplementation with VIT and Q –VIT for 28 days in trained cyclists. However, there 
were no significant differences between treatment VIT and Q - VIT in IL-6, CRP, and IL-10 
concentrations at any time points. There was a trend that the plasma CRP concentration for Q-
VIT was lower than VIT (p = 0.08). 
            In agreement with our study, several human studies have shown that there was no effect 
of chronic quercetin supplementation on exercise-induced inflammation. However, the timing of 
last quercetin supplementation before exercise needs to be carefully considered. Since plasma 
quercetin concentration peak at 120- 180 min after supplementation[35], performing exercise 2-3 
hours after supplementation is more reasonable in studies using quercetin as supplement. 
However, this is not the case in aforementioned studies. In the first study[14, 15], cyclists were 
randomized to 1,000 mg/day quercetin or placebo for three weeks and cycled three hours per day 
three days in a row at 57% watts-max. Subjects ingested only 500 mg before breakfast and 
performed exercise at 2 pm. Therefore, there was a seven hours gap between quercetin ingestion 
and the beginning of exercise. A second three weeks quercetin supplementation study with 
ultramarathon runners at the 160-km Western States Endurance Run also showed no effect of 
quercetin on exercise induced inflammation[16]. In the study, subjects ingested 1,000 mg 
quercetin each day for three weeks and then just prior to the 160-km race, but did not ingest 
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additional supplements throughout the race (an average 27 hour). Plasma quercetin levels 
dropped to very low levels in the quercetin group and were not different from the placebo group 
post-race.  
            Abbey et al. [19] performed a one week quercetin supplementation study with 1,000 
mg/d quercetin-3-glucoside also showed no effect on repeated-sprint performance, plasma 
xanthine oxidase activity, and IL-6. However, the supplementation duration was only one week, 
which is not enough for quercetin to accumulate in plasma at high level. Jin et al. [37] reported 
that it took four weeks for quercetin supplement to reach plateau in plasma. In addition, plasma 
quercetin concentration reaches peak level two to three hours after ingestion. However, subjects 
took their last quercetin supplement 15 minutes before exercise and the exercise trial lasted less 
than 30 minutes. Due to the duration of the supplementation and the timing of the last quercetin 
ingestion, we expected the plasma quercetin concentration were not high in their study and they 
did not report the data of plasma quercetin concentration. 
            Unlike most previous studies and present study found no effect of quercetin 
supplementation on markers of oxidative stress and inflammation[14-16, 19, 20]. Nieman et al. 
[17] showed that two weeks of quercetin combined with epigallocatechin 3-gallate (EGCG) 
supplementation resulted in significantly reduced post-exercise measures for both inflammation 
and oxidative stress. McAnulty et al. [18] also revealed that two weeks of quercetin combined 
with vitamin C, EGCG and n-3 fatty acids supplementation did not exhibit a significant increase 
in post-exercise oxidative stress. One potential reason of the inconsistent results in these study 
compares to our study is that two or more flavonoids ingested together may increase 
bioavailability and decrease elimination via competitive inhibition of glucuronide and sulfate 
conjugation in both the intestine and liver and via inhibiting efflux transporters [40], therefore 
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extend its bioactive effects. Another potential reason of inconsistent finding is that, in our study, 
there was no increase in plasma CRP level after exercise and plasma CRP concentration was 
very low at level around 0.012 mg/l. In previous study [17], plasma CRP increased to 8 mg/L in 
the placebo group after the third day of three hours per cycling suggests that the exercise load in 
our study was not enough to increase plasma CRP level and therefore less opportunity for 
quercetin to exert anti-inflammatory effect.  
         .  We chose quercetin without combination with flavonoids because our goal is to examine 
the effect of single flavonoids, quercetin, on exercise induced cytokine response. Even though 
previous study did not show any effect of quercetin alone without other flavonoids on exercise 
induced inflammation, the study designs were not optimal in terms of the duration of 
supplementation, the timing of last dose supplement, and the reality of the exercise protocol. 
Therefore, our goal was to investigate the effect of chronic supplementation of single flavonoids, 
quercetin, on exercise induced cytokine response in trained cyclists with better study design. In 
our study, the supplementation duration was four weeks, which has been shown enough for 
quercetin to accumulate in plasma and reach plateau[37], and to our knowledge, this is the first 
study using four weeks as supplementation duration and is longer than all the studies examining 
the effect of quercetin supplementation on exercise induced oxidative stress and inflammation. 
While MacRae et al. [57] found six weeks of quercetin base supplementation increase 
performance on a cycling time trial in trained cyclists, the supplementation contained caffeine 
which is generally known as a ergogenic aid in sport and they did not measure any markers of 
inflammation and oxidative stress. In terms of the timing of last dose supplement, the subjects in 
our study ingested 1,000 mg quercetin 2 hours before exercise which we expected the plasma 
quercetin concentration reached to peak level. In addition, the exercise duration in our study was 
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approximately an hour, therefore the plasma quercetin concentration was maintained at high 
level throughout the exercise trial.  Finally, our exercise protocol was a time trial very similar to 
a 30 kilometer time trial that competitive cyclists frequently perform. 
            We hypothesize that chronic quercetin supplementation will reduce exercise induced 
cytokine responses due to the anti-oxidative and anti-inflammatory capacities. The possible 
mechanism is that quercetin can neutralize ROS induced by intense aerobic cycling exercise, as 
during endurance exercise, oxygen consumption increases 10- to 20-fold systemically and as 
much as 100- to 200-fold at the level of the skeletal muscle, resulting in substantially increased 
mitochondrial electron flux. ROS ‘‘leaking’’ from the mitochondria during exercise are 
considered a main source of oxidative stress [47]. Quercetin is the most potent scavenger of ROS 
among flavonoid family [21, 22], and these antioxidant capacities of quercetin are attributed to 
the presence of two antioxidant pharmacophores within the molecule that has the optimal 
configuration for free radical scavenging. Since ROS can promote inflammatory processes via 
activation of transcription factors such as NF-κB which induce the production of cytokines like 
IL-6. Consequently, scavenging ROS by quercetin might not only prevent the occurrence of 
oxidative stress but also help mitigate inflammation.  
             In addition to ROS scavenging property of quercetin that exerts anti-oxidative and anti-
inflammatory effect, quercetin can directly regulate NF-κB without involving in ROS.  It has 
already been shown that quercetin can inhibit the degradation of the inhibitory part (IκBα) of 
NF-κB [34]. By decreasing the activation of NF-κB and as a result of decreasing the production 
of cytokines and inflammation. Therefore, quercetin can attenuate cytokines production by 
directly neutralizing ROS and/or inhibiting the activity of redox-sensitive signal transduction 
pathways such as NF-κB pathway. However, it should be emphasized that most data on 
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quercetin’s anti-oxidative and anti-inflammatory effect come from cell culture and animal 
studies. 
            Even with better study design in terms of supplementation duration and timing of last 
dose supplement ingestion, the result of our study, however, were consistent with previous 
human studies that failed to show that quercetin supplementation has effect on exercise induced 
cytokine response. There were no significant difference between treatment VIT and Q - VIT in 
IL-6, CRP, and IL-10 concentrations at any time points. One possible explanation is that the 
evidence presented from in vitro studies and rodents does not translate into in vivo human study 
with exercise induced oxidative stress and inflammation. In vitro/cell culture data indicate that 
quercetin in the aglycone form exerts impressive antioxidant and anti-inflammatory effect and 
inhibits cytokines production and gene expression through modulation NF-κB. However, 
quercetin undergoes considerable chemical modification during digestion and absorption and is 
metabolized to methylated, glucurono-sulfated derivate[39]. The quercetin conjugates may have 
altered biologic properties and potencies. Another factor to consider is that high quercetin 
concentrations used in cell culture studies may not apply to the low plasma concentrations 
achievable through oral supplementation in human studies. 
            Another explanation for lack effect of quercetin supplementation on exercise induced 
cytokine response in our study is that quercetin may have in vivo antioxidant function, but lack 
of linkage between oxidative stress and inflammation. ROS generated during exercise serve as 
critical messengers to activate the NF-κB which induce the production of cytokines such as IL-6. 
However, Nieman et al.[14] showed that exercise-induced increase in muscle cytokine mRNA 
without muscle NF-κB involvement. In fact, Pedersen[55] suggested that unlike IL-6 signalling 
in macrophages, which seems to be dependent upon the activation of the NF-κB signalling 
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pathway, intramuscular IL-6 expression is regulated by a network of signaling cascades that 
among other pathways are likely to involve crosstalk between the Ca2+/nuclear factor of 
activated T-cells (NFAT) and glycogen/p38 mitogen-activated protein kinase (MAPK) pathways. 
In addition, contracting skeletal muscle per se is the main source of the IL- 6 in the circulation in 
response to exercise[54]. Therefore, quercetin may preserve its antioxidant function and 
scavenge ROS generated during exercise. However, contracting skeletal muscles produced Il-6 
by different pathway independent of ROS regulation of NF-κB signalling pathway. As a result, 
both VIT and Q-VIT showed significant increase in plasma IL-6 concentration immediately after 
exercise (POST) to the same extent. Since IL-6 induced production of anti-inflammatory 
cytokine IL-10, the plasma IL-10 also increased to the same extent in both VIT and Q-VIT 
without treatment effect between them. 
             Elevation of CRP levels in blood is recognized as a marker of inflammation and is 
associated with an increased risk of cardiac disease [58], as well as the acute exercise response in 
healthy individuals. Quercetin and resveratrol suppressed cytokine-induced CRP expression in 
Hep3B cells[59]. Garcia-Mediavilla et al.[60] found that quercetin exhibited anti-inflammatory 
effects and subsequent reduction of CRP in Chang liver cells. In our study, similar to the plasma 
IL-6 and IL-10, no effect of quercetin was found in reducing CRP after heavy endurance exercise 
even though there was a trend that plasma CRP concentration for Q-VIT was lower than VIT (p 
= 0.08). 
           It should be emphasized that our subject population consisted of highly trained athletes 
who are known to possess up-regulated antioxidant defenses[61]. The presence of highly 
elevated antioxidant defense systems may have masked any beneficial effects of quercetin 
administration. It would be interesting to add another group using untrained individuals and 
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examine whether the untrained individuals with less endogenous antioxidant defenses will have 
different responses.   
           It should be also noticed that although excessive states of oxidative stress are likely 
detrimental, it is also known that oxidative stress from exercise also play fundamental roles in 
cell signaling and gene expression [62, 63]. Evidence suggests that antioxidant supplementation 
may in fact attenuate some of the exercise-induced cellular signals that stimulate adaptations in 
skeletal muscle and vascular tissue also exist [64-66]. The rationale for antioxidant 
supplementation in relation to intensive endurance exercise is to inhibit exercise induced 
inflammation. Inflammation is a double-edge sword, on one hand, inflammation is required in 
order to combat infection and acute injury and on the other hand, chronic systemic inflammation 
causes impaired metabolism. Therefore, when using antioxidant supplementation in an attempt to 
attenuated exercise induced inflammation, one should carefully control antioxidant dosage and 
exercise stress and cautiously examine actual consequences of antioxidant administration.   
           In addition, the role of IL-6 induced by exercise may very different from what was 
generally thought. It was commonly thought that the exercise-induced increase in IL-6 was a 
consequence of an immune response due to local damage in the working muscles [67], and it was 
hypothesized that the immune cells were responsible for this increase and leads to an 
inflammatory response[68]. Today, it is clear that the contracting skeletal muscle cells per se 
produce and release IL-6 without activating classical pro-inflammatory pathways [55]. In fact, 
muscle drives important IL-6 mediates autocrine, paracrine and endocrine functions. Thus IL-6 is 
involved in mediating glucose uptake in muscle, fat oxidation, lipolysis and possesses strong 
anti-inflammatory properties [69]. Therefore, an attenuate exercise induce cytokines response by 
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antioxidant supplementation may not actually be beneficial and further studies are needed to 
investigate the exercise induced cytokine response and inflammation. 
          There were limitations that must be realized in this study. The placebo (VIT) contained 
Vitamin C and Vitamin B3 in order to expound the effects of quercetin itself on exercise induced 
cytokine response, however the effect of the vitamin supplementation itself and the effect of 
quercetin itself cannot be determined with this design.  
             In conclusion, daily supplementation with the flavonoid quercetin for 28 days has no 
effect on intensive endurance induced cytokine response, including IL-6, CRP IL-10. However, 
there was a trend (p=0.08) that daily supplementation quercetin with vitamins for 28 days 
lowered the plasma CRP both before and after intensive endurance exercise compare to 
supplementation with vitamins alone. With intensive endurance exercise induced oxidative stress, 
cytokine response and inflammation are complicated and the intervention of antioxidants adds 
further complexity. Further research is needed to clarify whether the antioxidants 
supplementation is beneficial or detrimental.  
                    
      








APPENDIX: DATA TABLES 
Interleukin-6 
    VIT     Q - VIT   
Subject pre min20 post pre min20 Post 
3 2.927 4.729 28.574 5.090 6.259 28.920 
4 3.485 3.759 19.035 3.016 2.440 19.720 
5 1.461 2.724 20.414 2.635 3.016 17.211 
6 5.108 6.637 33.321 4.570 5.196 25.704 
7 3.918 3.997 22.398 4.844 4.835 22.216 
8 3.829 5.504 35.287 1.354 1.907 17.420 
9 3.600 4.324 22.840 5.028 5.636 25.160 
11 5.345 6.110 27.952 5.820 7.926 34.270 
12 2.387 3.034 25.782 2.688 3.379 36.623 
13 4.279 5.565 27.313 3.379 4.350 19.451 
19 3.175 4.606 28.790 4.720 6.382 27.831 
AVERAGE 3.592 4.635 26.519 3.922 4.666 24.957 



















    VIT     Q - VIT   
Subject pre min20 post pre min20 post 
3 11.967 16.065 15.194 8.673 7.252 7.190 
4 21.240 21.578 19.533 19.191 21.874 17.534 
5 5.037 6.631 5.487 7.614 6.866 5.136 
6 4.487 8.664 9.376 6.295 5.944 7.517 
7 4.601 4.601 4.863 2.470 2.722 2.879 
8 19.067 19.648 21.758 2.244 2.484 2.215 
9 4.850 5.496 4.858 2.604 2.753 2.661 
11 8.276 8.883 7.722 4.036 4.159 4.051 
12 13.172 13.738 14.734 1.613 1.775 1.840 
13 31.648 29.194 34.551 31.463 34.646 40.297 
19 3.700 4.013 4.221 5.742 6.781 5.949 
AVERAGE 11.640 12.592 12.936 8.359 8.841 8.843 

















    VIT     Q - VIT   
Subject pre min20 post pre min20 post 
3 1.444 1.208 1.047 0.234 0.234 0.300 
4 0.135 0.124 0.670 0.146 0.146 0.245 
5 0.278 0.300 0.442 0.311 0.322 0.289 
6 0.267 0.223 0.267 0.256 0.223 0.344 
7 0.278 0.157 0.464 0.322 0.289 0.311 
8 0.399 0.399 0.703 0.475 0.322 0.344 
9 0.209 0.209 0.493 0.190 0.275 0.748 
11 0.152 0.123 0.180 0.076 0.123 0.171 
12 0.341 0.512 0.275 0.246 0.303 0.360 
13 0.313 0.218 0.833 0.294 0.228 1.155 
19 0.407 0.483 1.155 0.455 0.455 1.401 
AVERAGE 0.384 0.360 0.594 0.273 0.266 0.515 
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